Cytomedix Completes the Second Tranche of the $35 Million Convertible Debt Financing With Deerfield Management Company
26 juin 2014 08h00 HE
|
Cytomedix, Inc.
GAITHERSBURG, Md., June 26, 2014 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, today announced receipt, following satisfaction of...
Cytomedix Reports 2014 First Quarter Financial Results
15 mai 2014 16h15 HE
|
Cytomedix, Inc.
GAITHERSBURG, Md., May 15, 2014 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, today reported financial results for the three...
Cytomedix to Host First Quarter 2014 Financial Results Conference Call on Friday, May 16, 2014
08 mai 2014 09h42 HE
|
Cytomedix, Inc.
GAITHERSBURG, Md., May 8, 2014 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, announced today that it will release financial...
Cytomedix Announces Results of RECOVER-Stroke Phase 2 Study; Provides Update on R&D Reorganization and Ongoing Launch Initiatives for AutoloGel(TM)
05 mai 2014 16h15 HE
|
Cytomedix, Inc.
Results from RECOVER-Stroke Phase 2 Trial Show No Significant Clinical Benefit; Completion of R&D Restructuring Expected to Lead to Additional Cost Savings;
Continued Strategic Focus on...
Cytomedix Announces Two AutoloGel(R) Presentations at the Symposium on Advanced Wound Care (SAWC) Spring Meeting
22 avr. 2014 16h00 HE
|
Cytomedix, Inc.
GAITHERSBURG, Md., April 22, 2014 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, today announced two key oral presentations and a...
Cytomedix Announces Appointment of Andrew Cohen as Vice President of Marketing
07 avr. 2014 08h00 HE
|
Cytomedix, Inc.
GAITHERSBURG, Md., April 7, 2014 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, announced today the appointment of Andrew Cohen as...
Cytomedix Announces Receipt of USPTO Allowance for Patent Covering Use of ALDH Bright Cells in Stroke
03 avr. 2014 08h00 HE
|
Cytomedix, Inc.
GAITHERSBURG, Md., April 3, 2014 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, and its wholly owned subsidiary, Aldagen, Inc.,...
Cytomedix Reports 2013 Fourth Quarter and Full Year Financial Results; Announces Up to $35 Million Convertible Debt Financing With Deerfield Management Company
31 mars 2014 16h30 HE
|
Cytomedix, Inc.
$2 Million Additional Equity Investment with Anson Group
Conference Call Scheduled for Tuesday, April 1st at 8:00 AM Eastern Time
GAITHERSBURG, Md., March 31, 2014 (GLOBE NEWSWIRE) --...
Cytomedix Announces Senior Management Appointments
31 mars 2014 16h30 HE
|
Cytomedix, Inc.
Industry Veteran and Wound Care Commercial Expert Dean Tozer Appointed as Executive Vice President and Chief Commercial Officer
Jennifer Linsky Appointed as Senior Director of National Accounts...
Cytomedix to Host Fourth Quarter & Fiscal Year End 2013 Financial Results Conference Call on Tuesday, April 1, 2014
25 mars 2014 08h00 HE
|
Cytomedix, Inc.
GAITHERSBURG, Md., March 25, 2014 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, announced today that it will release financial...